Subscribe to Tatva Chintan Pharma Chem: Hem Securities

Hem Securities has come out with its report on Tatva Chintan Pharma Chem. The research firm has recommended to ''Subscribe'' the ipo in its research report as on July 15, 2021.

Broker Research
July 16, 2021 / 02:33 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Hem Securities IPO report on Tatva Chintan Pharma Chem


Tatva Chintan is among the key players in the specialty chemicals segment, with its range of products finding applications among the high growth segments. Engaged in manufacturing of a variety of Disinfectants, Catalysts, Agro and Pharmaceuticals intermediates and other specialty intermediates, Tatva Chintan has a good product mix across sectors of Agrochemicals, Pharmaceuticals, Personal care, etc.



Valuation and Outlook


Looking after all above we recommend” Subscribe” ths issue for listing gain & long term purpose.


For all IPO stories, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Broker Research
Tags: #Hem Securities #IPO #IPO - Issues Open #IPO Broker Analysis #subscribe #Tatva Chintan Pharma Chem #Upcoming Issues
first published: Jul 16, 2021 02:33 pm